regeneron nasdaq - Search News

News

Regeneron To Buy 23andMe For $256M

Regeneron To Buy 23andMe For $256M After Bankruptcy: Here’s What To Know

Me, known for its at-home DNA testing kits, is expected to be obtained by its highest bidder following a bankruptcy auction after reaching a peak valuation of $6 billion.

Insider Monkey on MSN · 21h

Regeneron Pharmaceuticals to Acquire 23andMe for $256M

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced today that it will acquire 23andMe for a purchase price of $256 million. 23andMe had filed for bankruptcy protection in March this year, while REGN was the sole bidder for its assets.

FinanzNachrichten.de · 21h

23andMe, Inc.: Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

Regeneron Commits to Comply with Company's Privacy Policy and All Applicable Law; No Changes to 23andMe's Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO

23hon MSN

Regeneron to buy 23andMe for $256M in court-supervised sale

Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe for a purchase pric ...

InvestorsHub on MSN1d

Regeneron Shares Climb on Acquisition of 23andMe Assets in Bankruptcy Deal

Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock rise 2% after announcing it had secured a winning bid to acquire key ...

Nasdaq4d

Regeneron Pharmaceuticals Celebrates Jury Verdict Against Amgen for Antitrust Violations, Awarding $406.8 Million in Damages

In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...

3don MSN

Regeneron wins over $400M jury award as Amgen found liable in antitrust case

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

18h

OraSure stock rises following Regeneron’s 23andMe acquisition

The market’s positive reaction to OraSure’s stock today reflects investor confidence in the company’s ongoing relationship with 23andMe under Regeneron’s ownership. The continuation of this ...

Nasdaq5d

Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

21h

Regeneron stock rises on 23andMe assets acquisition

The planned purchase will allow Regeneron to integrate 23andMe’s extensive genetic data into its research efforts, potentially leading to new medical advancements. Regeneron has stated its commitment ...

Nasdaq6d

Citigroup Upgrades Regeneron Pharmaceuticals (LSE:0R2M)

There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals ... author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Mason Hawkins' Strategic Move: Regeneron Pharmaceuticals Inc. Takes Center Stage

The most significant addition was Regeneron Pharmaceuticals Inc (NASDAQ:REGN), with 114,880 shares, accounting for 3.88% of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results